We perform whole-body cancer screening by testing 16 tumor markers along with blood cell component analysis and inflammatory response markers.
This includes screening for cancers such as esophageal, gastric, colorectal, liver, gallbladder, bile duct, pancreatic, lung, ovarian, breast, prostate, hematologic cancers, lymphoma, and more.
Please note: Tumor markers are primarily used for follow-up after cancer treatment. A positive result does not directly mean that cancer is present.
By measuring antibodies to Helicobacter pylori and the level of pepsinogen, we can evaluate the future risk of gastric cancer using the A, B, C classification.
In addition, treatment such as H. pylori eradication or stomach medication can help reduce this risk.
